Lixte Biotechnology Enters Material Agreement
Ticker: LIXT · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: LIXT
TL;DR
LIXT signed a big deal on 6/10, filing shows financials.
AI Summary
Lixte Biotechnology Holdings, Inc. entered into a Material Definitive Agreement on June 10, 2024. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing indicates a significant development for Lixte Biotechnology, potentially impacting its operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- June 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 202903526 (id_number) — I.R.S. Employer Identification Number
FAQ
What is the nature of the Material Definitive Agreement entered into by Lixte Biotechnology Holdings, Inc.?
The filing states that Lixte Biotechnology Holdings, Inc. entered into a Material Definitive Agreement on June 10, 2024, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 10, 2024.
In which state was Lixte Biotechnology Holdings, Inc. incorporated?
Lixte Biotechnology Holdings, Inc. was incorporated in Delaware.
What is the I.R.S. Employer Identification Number for Lixte Biotechnology Holdings, Inc.?
The I.R.S. Employer Identification Number for Lixte Biotechnology Holdings, Inc. is 20-2903526.
What other items are included in this 8-K filing besides the material agreement?
In addition to the entry into a Material Definitive Agreement, this 8-K filing also includes Financial Statements and Exhibits.
Filing Stats: 777 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-06-14 08:30:20
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex10-1.htm (EX-10.1) — 622KB
- 0001493152-24-023798.txt ( ) — 949KB
- lixt-20240610.xsd (EX-101.SCH) — 4KB
- lixt-20240610_def.xml (EX-101.DEF) — 26KB
- lixt-20240610_lab.xml (EX-101.LAB) — 36KB
- lixt-20240610_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 14, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer 3 INDEX TO EXHIBITS Exhibit No. Description 10.1 Clinical Trial Agreement dated as of June 10, 2024 between the Company and the Netherlands Cancer Institute. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 4